PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25122444-0	2015	A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.	C 1027	141-150	epidermal growth factor receptor	Homo sapiens	159-163
27882937-0	2016	EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.	C 1027	14-23	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
27882937-0	2016	EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.	C 1027	14-23	H3 histone pseudogene 16	Homo sapiens	71-74
26457548-2	2016	Lidamycin (LDM) is composed of another active enediyne chromophore (AE) and an acidic protein (LDP).	C 1027	0-9	carboxypeptidase Q	Homo sapiens	95-98
26314845-4	2015	Considering the facts that TIMP2, the tissue inhibitor of metalloproteinase 2, shows specific interaction with MMP-14 and that Lidamycin (LDM), an extremely potent cytotoxic antitumor antibiotic, consists of an apoprotein (LDP) and a highly active enediyne (AE); we designed and prepared a TIMP2-based and enediyne-integrated fusion protein LDP(AE)-TIMP2 by DNA recombination and molecular reconstitution consecutively.	C 1027	127-136	TIMP metallopeptidase inhibitor 2	Homo sapiens	27-32
26314845-4	2015	Considering the facts that TIMP2, the tissue inhibitor of metalloproteinase 2, shows specific interaction with MMP-14 and that Lidamycin (LDM), an extremely potent cytotoxic antitumor antibiotic, consists of an apoprotein (LDP) and a highly active enediyne (AE); we designed and prepared a TIMP2-based and enediyne-integrated fusion protein LDP(AE)-TIMP2 by DNA recombination and molecular reconstitution consecutively.	C 1027	127-136	carboxypeptidase Q	Homo sapiens	223-226
26314845-4	2015	Considering the facts that TIMP2, the tissue inhibitor of metalloproteinase 2, shows specific interaction with MMP-14 and that Lidamycin (LDM), an extremely potent cytotoxic antitumor antibiotic, consists of an apoprotein (LDP) and a highly active enediyne (AE); we designed and prepared a TIMP2-based and enediyne-integrated fusion protein LDP(AE)-TIMP2 by DNA recombination and molecular reconstitution consecutively.	C 1027	127-136	TIMP metallopeptidase inhibitor 2	Homo sapiens	290-295
26314845-4	2015	Considering the facts that TIMP2, the tissue inhibitor of metalloproteinase 2, shows specific interaction with MMP-14 and that Lidamycin (LDM), an extremely potent cytotoxic antitumor antibiotic, consists of an apoprotein (LDP) and a highly active enediyne (AE); we designed and prepared a TIMP2-based and enediyne-integrated fusion protein LDP(AE)-TIMP2 by DNA recombination and molecular reconstitution consecutively.	C 1027	127-136	carboxypeptidase Q	Homo sapiens	341-344
26314845-4	2015	Considering the facts that TIMP2, the tissue inhibitor of metalloproteinase 2, shows specific interaction with MMP-14 and that Lidamycin (LDM), an extremely potent cytotoxic antitumor antibiotic, consists of an apoprotein (LDP) and a highly active enediyne (AE); we designed and prepared a TIMP2-based and enediyne-integrated fusion protein LDP(AE)-TIMP2 by DNA recombination and molecular reconstitution consecutively.	C 1027	127-136	TIMP metallopeptidase inhibitor 2	Homo sapiens	290-295
25122444-0	2015	A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.	C 1027	141-150	TNF receptor superfamily member 10a	Homo sapiens	168-173
25122444-7	2015	From IC50 values, bispecific and bifunctional energized fusion protein Ec-LDP-TRAIL-AE was more potent and selective in its cytotoxicity against different carcinoma cell lines than corresponding lidamycin in vitro and induction of the cleavage of poly(ADP-ribose)polymerase was observed in A431 cells treated with Ec-LDP-TRAIL-AE and lidamycin, respectively.	C 1027	195-204	carboxypeptidase Q	Homo sapiens	74-77
25122444-7	2015	From IC50 values, bispecific and bifunctional energized fusion protein Ec-LDP-TRAIL-AE was more potent and selective in its cytotoxicity against different carcinoma cell lines than corresponding lidamycin in vitro and induction of the cleavage of poly(ADP-ribose)polymerase was observed in A431 cells treated with Ec-LDP-TRAIL-AE and lidamycin, respectively.	C 1027	195-204	TNF superfamily member 10	Homo sapiens	78-83
25122444-7	2015	From IC50 values, bispecific and bifunctional energized fusion protein Ec-LDP-TRAIL-AE was more potent and selective in its cytotoxicity against different carcinoma cell lines than corresponding lidamycin in vitro and induction of the cleavage of poly(ADP-ribose)polymerase was observed in A431 cells treated with Ec-LDP-TRAIL-AE and lidamycin, respectively.	C 1027	334-343	carboxypeptidase Q	Homo sapiens	74-77
25122444-7	2015	From IC50 values, bispecific and bifunctional energized fusion protein Ec-LDP-TRAIL-AE was more potent and selective in its cytotoxicity against different carcinoma cell lines than corresponding lidamycin in vitro and induction of the cleavage of poly(ADP-ribose)polymerase was observed in A431 cells treated with Ec-LDP-TRAIL-AE and lidamycin, respectively.	C 1027	334-343	TNF superfamily member 10	Homo sapiens	78-83
24664246-3	2014	The fusion protein Ec-LDP-Hr-AE consists of two oligopeptide ligands and an enediyne antibiotic lidamycin (LDM) for receptor binding and cell killing, respectively.	C 1027	96-105	carboxypeptidase Q	Homo sapiens	22-25
24709078-0	2014	Lidamycin regulates p53 expression by repressing Oct4 transcription.	C 1027	0-9	tumor protein p53	Homo sapiens	20-23
24709078-0	2014	Lidamycin regulates p53 expression by repressing Oct4 transcription.	C 1027	0-9	POU class 5 homeobox 1	Homo sapiens	49-53
26186454-3	2015	Lidamycin(LDM) is a novel antibiotic composed of an apoprotein (LDP) and a chromophore (AE).	C 1027	0-9	carboxypeptidase Q	Homo sapiens	64-67
23857500-0	2015	Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3beta/beta-catenin pathway.	C 1027	0-9	MIR7-3 host gene	Homo sapiens	70-74
23857500-0	2015	Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3beta/beta-catenin pathway.	C 1027	0-9	glycogen synthase kinase 3 beta	Homo sapiens	83-91
23857500-0	2015	Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3beta/beta-catenin pathway.	C 1027	0-9	catenin beta 1	Homo sapiens	92-104
23857500-4	2015	Flow cytometry analysis and sorting assay, surface marker assay, sphere formation assay, and aldefluor assay were used to evaluate the effect of lidamycin on Huh7 tumor initiating cells in vitro.	C 1027	145-154	MIR7-3 host gene	Homo sapiens	158-162
23857500-6	2015	Subcutaneous tumor model in nude mice was used to observe in vivo effect of lidamycin on Huh7 cells.	C 1027	76-85	MIR7-3 host gene	Homo sapiens	89-93
23857500-7	2015	Lidamycin decreased the proportion of EpCAM+ cells and the expression of EpCAM protein.	C 1027	0-9	epithelial cell adhesion molecule	Homo sapiens	38-43
23857500-7	2015	Lidamycin decreased the proportion of EpCAM+ cells and the expression of EpCAM protein.	C 1027	0-9	epithelial cell adhesion molecule	Homo sapiens	73-78
23857500-8	2015	Lidamycin inhibited sphere formation of sorted EpCAM+ cells in 7 d, and of parental cells in three serial passages.	C 1027	0-9	epithelial cell adhesion molecule	Homo sapiens	47-52
23857500-11	2015	Lidamycin activated GSK3beta, and degraded the activity of beta-catenin.	C 1027	0-9	glycogen synthase kinase 3 beta	Homo sapiens	20-28
23857500-11	2015	Lidamycin activated GSK3beta, and degraded the activity of beta-catenin.	C 1027	0-9	catenin beta 1	Homo sapiens	59-71
23857500-13	2015	In brief, these results suggest that lidamycin suppressed Huh7 tumor initiating cells via GSK3beta/beta-catenin pathway.	C 1027	37-46	MIR7-3 host gene	Homo sapiens	58-62
23857500-13	2015	In brief, these results suggest that lidamycin suppressed Huh7 tumor initiating cells via GSK3beta/beta-catenin pathway.	C 1027	37-46	glycogen synthase kinase 3 beta	Homo sapiens	90-98
23857500-13	2015	In brief, these results suggest that lidamycin suppressed Huh7 tumor initiating cells via GSK3beta/beta-catenin pathway.	C 1027	37-46	catenin beta 1	Homo sapiens	99-111
25164878-3	2014	Lidamycin (LDM) that displays extremely potent cytotoxicity to cancer cells is composed of an apoprotein (LDP) and an enediyne chromophore (AE).	C 1027	0-9	carboxypeptidase Q	Homo sapiens	106-109
24128285-4	2013	Lidamycin (LDM), which consists of an active enediyne chromophore (AE) and a non-covalently bound apo-protein (LDP), is a member of chromoprotein family of antitumor antibiotics with extremely potent cytotoxicity to cancer cells.	C 1027	0-9	carboxypeptidase Q	Homo sapiens	111-114
25227788-2	2014	To investigate the potentiation of antitumor efficacy of lidamycin (LDM), an enediyne agent by the Hsp90 inhibitor geldanamycin (GDM), and possible mechanisms, we have determined effects on ovarian cancer SKOV- 3, hepatoma Bel-7402 and HepG2 cells by MTT assay, apoptosis assay, and cell cycle analysis.	C 1027	57-66	heat shock protein 90 alpha family class A member 1	Homo sapiens	99-104
23975242-0	2013	Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.	C 1027	0-9	thymidine phosphorylase	Mus musculus	41-64
20596749-0	2011	Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.	C 1027	55-64	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	123-127
24137414-0	2013	Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma.	C 1027	23-32	coagulation factor III	Mus musculus	0-13
23206754-3	2013	Lidamycin is a highly potent antitumor antibiotic, which is composed of an apoprotein (LDP) and an active enediyne chromophore (AE).	C 1027	0-9	carboxypeptidase Q	Homo sapiens	87-90
23206754-4	2013	Here, an NGR-integrated and enediyne-energized apoprotein composed of cyclic NGR peptide and lidamycin was developed by a two-step procedure.	C 1027	93-102	reticulon 4 receptor	Homo sapiens	9-12
22480685-0	2012	Lidamycin induces neural differentiation of mouse embryonic carcinoma cells through down-regulation of transcription factor Oct4.	C 1027	0-9	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	124-128
22480685-4	2012	It was observed that lidamycin decreased transcription factor Oct4, and increased both p21 mRNA and protein expression in P19 EC cells.	C 1027	21-30	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	62-66
22480685-4	2012	It was observed that lidamycin decreased transcription factor Oct4, and increased both p21 mRNA and protein expression in P19 EC cells.	C 1027	21-30	transcription elongation factor A (SII)-like 1	Mus musculus	87-90
22480685-4	2012	It was observed that lidamycin decreased transcription factor Oct4, and increased both p21 mRNA and protein expression in P19 EC cells.	C 1027	21-30	interleukin 23, alpha subunit p19	Mus musculus	122-125
22480685-5	2012	Furthermore, luciferase assay showed that lidamycin activated p21 promoter activity through suppression of Oct4, and Chromatin immunoprecipitation (ChIP) assay confirmed that binding of transcription factor Oct4 to the p21 promoter decreased in lidamycin-exposed cells.	C 1027	42-51	transcription elongation factor A (SII)-like 1	Mus musculus	62-65
22480685-5	2012	Furthermore, luciferase assay showed that lidamycin activated p21 promoter activity through suppression of Oct4, and Chromatin immunoprecipitation (ChIP) assay confirmed that binding of transcription factor Oct4 to the p21 promoter decreased in lidamycin-exposed cells.	C 1027	42-51	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	107-111
22480685-5	2012	Furthermore, luciferase assay showed that lidamycin activated p21 promoter activity through suppression of Oct4, and Chromatin immunoprecipitation (ChIP) assay confirmed that binding of transcription factor Oct4 to the p21 promoter decreased in lidamycin-exposed cells.	C 1027	42-51	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	207-211
22480685-5	2012	Furthermore, luciferase assay showed that lidamycin activated p21 promoter activity through suppression of Oct4, and Chromatin immunoprecipitation (ChIP) assay confirmed that binding of transcription factor Oct4 to the p21 promoter decreased in lidamycin-exposed cells.	C 1027	42-51	transcription elongation factor A (SII)-like 1	Mus musculus	219-222
22480685-5	2012	Furthermore, luciferase assay showed that lidamycin activated p21 promoter activity through suppression of Oct4, and Chromatin immunoprecipitation (ChIP) assay confirmed that binding of transcription factor Oct4 to the p21 promoter decreased in lidamycin-exposed cells.	C 1027	245-254	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	207-211
22480685-5	2012	Furthermore, luciferase assay showed that lidamycin activated p21 promoter activity through suppression of Oct4, and Chromatin immunoprecipitation (ChIP) assay confirmed that binding of transcription factor Oct4 to the p21 promoter decreased in lidamycin-exposed cells.	C 1027	245-254	transcription elongation factor A (SII)-like 1	Mus musculus	219-222
22480685-7	2012	In accordance, overexpression of Oct4 blocked neural differentiation and down-regulated p21 in lidamycin-treated P19 cells.	C 1027	95-104	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	33-37
22480685-7	2012	In accordance, overexpression of Oct4 blocked neural differentiation and down-regulated p21 in lidamycin-treated P19 cells.	C 1027	95-104	transcription elongation factor A (SII)-like 1	Mus musculus	88-91
22480685-7	2012	In accordance, overexpression of Oct4 blocked neural differentiation and down-regulated p21 in lidamycin-treated P19 cells.	C 1027	95-104	interleukin 23, alpha subunit p19	Mus musculus	113-116
22480685-8	2012	Taken together, these results suggested that neuronal differentiation of EC cells induced by lidamycin was associated with the inhibition of Oct4 expression and the activation of p21 transcription.	C 1027	93-102	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	141-145
22480685-8	2012	Taken together, these results suggested that neuronal differentiation of EC cells induced by lidamycin was associated with the inhibition of Oct4 expression and the activation of p21 transcription.	C 1027	93-102	transcription elongation factor A (SII)-like 1	Mus musculus	179-182
22365395-1	2011	OBJECTIVE: Lidamycin (LDM) can be dissociated to an apoprotein (LDP) and an active enediyne chromophore (AE).	C 1027	11-20	carboxypeptidase Q	Homo sapiens	64-67
22365395-11	2011	CONCLUSION: The assembly rate of chromophore of lidamycin with its LDP-containing fusion protein was improved after condition optimization by orthogonal design, and the optimal conditions described herein should prove useful for the development of this type of LDP-containing fusion protein.	C 1027	48-57	carboxypeptidase Q	Homo sapiens	67-70
22365395-11	2011	CONCLUSION: The assembly rate of chromophore of lidamycin with its LDP-containing fusion protein was improved after condition optimization by orthogonal design, and the optimal conditions described herein should prove useful for the development of this type of LDP-containing fusion protein.	C 1027	48-57	carboxypeptidase Q	Homo sapiens	261-264
23599760-2	2013	Lidamycin is an enediyne antitumor antibiotic, which is composed of an apoprotein (LDP) and an active chromophore (AE).	C 1027	0-9	carboxypeptidase Q	Homo sapiens	83-86
22205154-3	2012	A fusion protein ER(Fv-LDP), consisting of an anti-EGFR scFv and the apoprotein (LDP) of lidamycin (LDM), was prepared and then assembled with the active chomophore [active enediyne (AE)] of LDM to generate enediyne-energized analogue ER(Fv-LDP-AE).	C 1027	89-98	carboxypeptidase Q	Homo sapiens	23-26
22205154-3	2012	A fusion protein ER(Fv-LDP), consisting of an anti-EGFR scFv and the apoprotein (LDP) of lidamycin (LDM), was prepared and then assembled with the active chomophore [active enediyne (AE)] of LDM to generate enediyne-energized analogue ER(Fv-LDP-AE).	C 1027	89-98	carboxypeptidase Q	Homo sapiens	81-84
22205154-3	2012	A fusion protein ER(Fv-LDP), consisting of an anti-EGFR scFv and the apoprotein (LDP) of lidamycin (LDM), was prepared and then assembled with the active chomophore [active enediyne (AE)] of LDM to generate enediyne-energized analogue ER(Fv-LDP-AE).	C 1027	89-98	carboxypeptidase Q	Homo sapiens	81-84
20596749-0	2011	Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.	C 1027	55-64	SRY (sex determining region Y)-box 2	Mus musculus	129-133
20596749-0	2011	Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.	C 1027	55-64	myelocytomatosis oncogene	Mus musculus	138-141
21355209-0	2010	[Lidamycin inhibits angiogenesis of zebrafish embryo via down-regulation of VEGF].	C 1027	1-10	vascular endothelial growth factor Aa	Danio rerio	76-80
22260022-0	2011	[Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].	C 1027	1-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	41-45
22260022-1	2011	This study is to investigate inhibitory effects of lidamycin (LDM) on the proliferation of HERG K+ channel highly expressing cancer cells and its synergy with anticancer drugs.	C 1027	51-60	potassium voltage-gated channel subfamily H member 2	Homo sapiens	91-95
22260022-2	2011	MTT assay was used to examine the inhibitory effects of lidamycin combined with various anticancer drugs on the proliferation of human lung cancer A549 cells, human colon cancer HT-29 cells and herg-stably-transfected A549 cells.	C 1027	56-65	potassium voltage-gated channel subfamily H member 2	Homo sapiens	194-198
19845765-4	2009	Overexpression of cagA in the wild-type strain resulted in a significant increase in C-1027 production as expected.	C 1027	85-91	S100 calcium binding protein A8	Homo sapiens	18-22
19502782-0	2009	Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.	C 1027	93-102	checkpoint kinase 1	Homo sapiens	13-17
19737585-1	2009	The molecule of lidamycin that belongs to the chromoprotein family of antitumor antibiotics is composed of an apoprotein (LDP) and an enediyne chromophore.	C 1027	16-25	carboxypeptidase Q	Homo sapiens	122-125
19502782-0	2009	Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.	C 1027	93-102	tumor protein p53	Homo sapiens	69-72
19502782-2	2009	In this study, we investigate whether knockdowns of checkpoint kinases Chk1 and Chk2 by RNA interfering potentiate the cytotoxicity and abrogate G(2)/M checkpoint induced by DNA-damaging agent lidamycin (LDM) in HCT116 cells with different p53 status.	C 1027	193-202	checkpoint kinase 1	Homo sapiens	71-75
19502782-2	2009	In this study, we investigate whether knockdowns of checkpoint kinases Chk1 and Chk2 by RNA interfering potentiate the cytotoxicity and abrogate G(2)/M checkpoint induced by DNA-damaging agent lidamycin (LDM) in HCT116 cells with different p53 status.	C 1027	193-202	checkpoint kinase 2	Homo sapiens	80-84
17487403-0	2007	Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.	C 1027	48-57	nuclear factor kappa B subunit 1	Homo sapiens	23-44
17534142-0	2007	P53 dependent and independent apoptosis induced by lidamycin in human colorectal cancer cells.	C 1027	51-60	tumor protein p53	Homo sapiens	0-3
17534142-3	2007	Here we reported the involvement of p53 signaling pathway in apoptosis induction by lidamycin (LDM), a member of the enediyne antibiotic family.	C 1027	84-93	tumor protein p53	Homo sapiens	36-39
19635191-7	2009	The energized fusion protein Ec-LDP-AE was prepared by integrating the active enediyne chromophore (AE) of lidamycin into the Ec-LDP protein.	C 1027	107-116	carboxypeptidase Q	Homo sapiens	32-35
19725468-8	2009	RESULTS: SIRT1 deacetylase remained unchanged in 0.5 nmol/L lidamycin whereas cleavage occurred when apoptosis was induced by lidamycin.	C 1027	60-69	sirtuin 1	Homo sapiens	9-14
19725468-9	2009	Increased FOXO3a, SOD-1 and SOD-2 expression and transient phosphorylation of ERK were detected after exposure of human hepatoma BEL-7402 cells to 0.5 nmol/L lidamycin.	C 1027	158-167	forkhead box O3	Homo sapiens	10-16
19725468-9	2009	Increased FOXO3a, SOD-1 and SOD-2 expression and transient phosphorylation of ERK were detected after exposure of human hepatoma BEL-7402 cells to 0.5 nmol/L lidamycin.	C 1027	158-167	superoxide dismutase 1	Homo sapiens	18-23
19725468-9	2009	Increased FOXO3a, SOD-1 and SOD-2 expression and transient phosphorylation of ERK were detected after exposure of human hepatoma BEL-7402 cells to 0.5 nmol/L lidamycin.	C 1027	158-167	superoxide dismutase 2	Homo sapiens	28-33
19725468-9	2009	Increased FOXO3a, SOD-1 and SOD-2 expression and transient phosphorylation of ERK were detected after exposure of human hepatoma BEL-7402 cells to 0.5 nmol/L lidamycin.	C 1027	158-167	mitogen-activated protein kinase 1	Homo sapiens	78-81
19725468-10	2009	High expressions of SIRT1 and Akt were found in colon carcinoma HCT116 p53 knock-out cells exposed to lidamycin.	C 1027	102-111	sirtuin 1	Homo sapiens	20-25
19725468-10	2009	High expressions of SIRT1 and Akt were found in colon carcinoma HCT116 p53 knock-out cells exposed to lidamycin.	C 1027	102-111	AKT serine/threonine kinase 1	Homo sapiens	30-33
19725468-10	2009	High expressions of SIRT1 and Akt were found in colon carcinoma HCT116 p53 knock-out cells exposed to lidamycin.	C 1027	102-111	tumor protein p53	Homo sapiens	71-74
19725468-11	2009	Degradation of PARP and p53 by lidamycin as a substitute for SIRT1 and Akt was confirmed with caspase inhibitor Q-VD-OPh and proteasome inhibitor MG132.	C 1027	31-40	collagen type XI alpha 2 chain	Homo sapiens	15-19
19725468-11	2009	Degradation of PARP and p53 by lidamycin as a substitute for SIRT1 and Akt was confirmed with caspase inhibitor Q-VD-OPh and proteasome inhibitor MG132.	C 1027	31-40	tumor protein p53	Homo sapiens	24-27
19725468-15	2009	CONCLUSIONS: Cellular prosurvival molecules, such as SIRT1, Akt, SOD-1, SOD-2 and other unknown factors can influence the action of lidamycin on human tumor cells.	C 1027	132-141	sirtuin 1	Homo sapiens	53-58
19725468-15	2009	CONCLUSIONS: Cellular prosurvival molecules, such as SIRT1, Akt, SOD-1, SOD-2 and other unknown factors can influence the action of lidamycin on human tumor cells.	C 1027	132-141	AKT serine/threonine kinase 1	Homo sapiens	60-63
19725468-15	2009	CONCLUSIONS: Cellular prosurvival molecules, such as SIRT1, Akt, SOD-1, SOD-2 and other unknown factors can influence the action of lidamycin on human tumor cells.	C 1027	132-141	superoxide dismutase 1	Homo sapiens	65-70
19725468-15	2009	CONCLUSIONS: Cellular prosurvival molecules, such as SIRT1, Akt, SOD-1, SOD-2 and other unknown factors can influence the action of lidamycin on human tumor cells.	C 1027	132-141	superoxide dismutase 2	Homo sapiens	72-77
17978180-1	2007	The ability of the radiomimetic anticancer enediyne C-1027 to induce ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR)-independent damage responses was discovered to reside in its unique ability to concurrently generate robust amounts of double-strand breaks (DSBs) and interstrand cross-links (ICLs) in cellular DNA.	C 1027	52-58	ATM serine/threonine kinase	Homo sapiens	69-98
17978180-1	2007	The ability of the radiomimetic anticancer enediyne C-1027 to induce ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR)-independent damage responses was discovered to reside in its unique ability to concurrently generate robust amounts of double-strand breaks (DSBs) and interstrand cross-links (ICLs) in cellular DNA.	C 1027	52-58	ATM serine/threonine kinase	Homo sapiens	100-103
17978180-1	2007	The ability of the radiomimetic anticancer enediyne C-1027 to induce ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR)-independent damage responses was discovered to reside in its unique ability to concurrently generate robust amounts of double-strand breaks (DSBs) and interstrand cross-links (ICLs) in cellular DNA.	C 1027	52-58	ATM serine/threonine kinase	Homo sapiens	109-112
17978180-1	2007	The ability of the radiomimetic anticancer enediyne C-1027 to induce ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR)-independent damage responses was discovered to reside in its unique ability to concurrently generate robust amounts of double-strand breaks (DSBs) and interstrand cross-links (ICLs) in cellular DNA.	C 1027	52-58	ATR serine/threonine kinase	Homo sapiens	131-134
11918851-7	2002	The extrons and introns of active N-ras gene in the BEL-7402 cells were easily damaged by lidamycin at low concentrations, but no damage in the silent IL-2 gene was observed.	C 1027	90-99	NRAS proto-oncogene, GTPase	Homo sapiens	34-39
17290610-0	2006	[Chemosensitivity of mdr1 gene overexpressed multidrug resistant cancer cells to lidamycin].	C 1027	81-90	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
17290610-1	2006	AIM: To investigate the chemosensitivity to lidamycin (C-1027) in mdr1 gene overexpressing cancer cell lines established by drug induction and by gene-transfection.	C 1027	44-53	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
17290610-1	2006	AIM: To investigate the chemosensitivity to lidamycin (C-1027) in mdr1 gene overexpressing cancer cell lines established by drug induction and by gene-transfection.	C 1027	55-61	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
17290610-6	2006	The chemosensitivity of cancer cells with low or high mdr1 expression to lidamycin and other antitumor drugs was tested by MTT assay.	C 1027	73-82	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
17290610-9	2006	Compared with parental cells, the values of resistant fold for KBv200, MCF-7/ADR and HepG2/mdr1 cells to lidamycin were 6.8, 1.6 and 1.3 fold; to adriamycin were 37.2, 181.3 and 8.8 fold; to taxol were 336.8, 49.2 and 40.3 fold, respectively.	C 1027	105-114	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
16533058-2	2006	However, we previously showed that cells lacking ATM robustly activate p53 in response to DNA strand breaks induced by the radiomimetic enediyne C-1027.	C 1027	145-151	ATM serine/threonine kinase	Homo sapiens	49-52
16533058-2	2006	However, we previously showed that cells lacking ATM robustly activate p53 in response to DNA strand breaks induced by the radiomimetic enediyne C-1027.	C 1027	145-151	tumor protein p53	Homo sapiens	71-74
16533058-3	2006	To gain insight into the nature of C-1027-induced ATM-independent damage responses to DNA DSBs, we further examined the molecular mechanisms underlying the cellular response to this unique radiomimetic agent.	C 1027	35-41	ATM serine/threonine kinase	Homo sapiens	50-53
16533058-5	2006	In the presence of ATM, but under ATM and Rad3-related kinase (ATR) deficient conditions, C-1027 treatment resulted in a decrease in the level of Chk1 phosphorylation but not in the level of p53 and Chk2 phosphorylation.	C 1027	90-96	ATM serine/threonine kinase	Homo sapiens	19-22
16533058-5	2006	In the presence of ATM, but under ATM and Rad3-related kinase (ATR) deficient conditions, C-1027 treatment resulted in a decrease in the level of Chk1 phosphorylation but not in the level of p53 and Chk2 phosphorylation.	C 1027	90-96	ATM serine/threonine kinase	Homo sapiens	34-37
16533058-5	2006	In the presence of ATM, but under ATM and Rad3-related kinase (ATR) deficient conditions, C-1027 treatment resulted in a decrease in the level of Chk1 phosphorylation but not in the level of p53 and Chk2 phosphorylation.	C 1027	90-96	ATR serine/threonine kinase	Homo sapiens	63-66
16533058-5	2006	In the presence of ATM, but under ATM and Rad3-related kinase (ATR) deficient conditions, C-1027 treatment resulted in a decrease in the level of Chk1 phosphorylation but not in the level of p53 and Chk2 phosphorylation.	C 1027	90-96	checkpoint kinase 1	Homo sapiens	146-150
16496675-0	2005	Lidamycin inhibits the cancer cell PKC activity induced by basic fibroblast growth factor.	C 1027	0-9	fibroblast growth factor 2	Rattus norvegicus	59-89
16496675-1	2005	AIM: To study the mechanism of inhibition of basic fibroblast growth factor (bFGF) related signal transduction by lidamycin in cancer cells.	C 1027	114-123	fibroblast growth factor 2	Rattus norvegicus	45-75
16496675-1	2005	AIM: To study the mechanism of inhibition of basic fibroblast growth factor (bFGF) related signal transduction by lidamycin in cancer cells.	C 1027	114-123	fibroblast growth factor 2	Rattus norvegicus	77-81
15606017-4	2004	The concentration-time profile in mice after iv lidamycin of 100, 50 and 10 microg x kg(-1) was best fitted with 2-compartmental model with T1/2alpha and T1/2beta of 0.77-1.8 min and 5.6-7.2 min, respectively.	C 1027	48-57	brachyury, T-box transcription factor T	Mus musculus	140-149
15606017-4	2004	The concentration-time profile in mice after iv lidamycin of 100, 50 and 10 microg x kg(-1) was best fitted with 2-compartmental model with T1/2alpha and T1/2beta of 0.77-1.8 min and 5.6-7.2 min, respectively.	C 1027	48-57	brachyury, T-box transcription factor T	Mus musculus	154-162
12889121-12	2003	The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells.	C 1027	70-79	BCL2 apoptosis regulator	Homo sapiens	96-101
12889121-12	2003	The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells.	C 1027	70-79	BCL2 apoptosis regulator	Homo sapiens	196-201
12889121-13	2003	CONCLUSION: The results suggest that lidamycin enhancement of cisplatin-induced apoptosis associates with decrease of Bcl-2 protein expression, which may be useful for cancer chemotherapy.	C 1027	37-46	BCL2 apoptosis regulator	Homo sapiens	118-123
17273739-0	2007	Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway.	C 1027	0-9	mitogen-activated protein kinase 14	Homo sapiens	105-108
16533058-5	2006	In the presence of ATM, but under ATM and Rad3-related kinase (ATR) deficient conditions, C-1027 treatment resulted in a decrease in the level of Chk1 phosphorylation but not in the level of p53 and Chk2 phosphorylation.	C 1027	90-96	checkpoint kinase 2	Homo sapiens	199-203
11724580-5	2001	Treatment with low levels of C-1027 (1-3 nM) does not result in the presence of a replication inhibitor in cell extracts, but they are deficient in replication protein A (RPA) function.	C 1027	29-35	replication protein A1	Homo sapiens	148-169
11724580-5	2001	Treatment with low levels of C-1027 (1-3 nM) does not result in the presence of a replication inhibitor in cell extracts, but they are deficient in replication protein A (RPA) function.	C 1027	29-35	replication protein A1	Homo sapiens	171-174
11724580-9	2001	The trans-acting inhibitor of DNA replication induced by treatment of cells with high levels of C-1027 (10 nM) is DNA-dependent protein kinase (DNA-PK).	C 1027	96-102	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	114-142
11724580-9	2001	The trans-acting inhibitor of DNA replication induced by treatment of cells with high levels of C-1027 (10 nM) is DNA-dependent protein kinase (DNA-PK).	C 1027	96-102	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	144-150
11724580-10	2001	DNA-PK is activated by the presence of DNA fragments induced by C-1027 treatment, and can be abrogated by removal of the DNA fragments.	C 1027	64-70	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-6
12901099-2	2001	METHODS: The mAb conjugate was prepared by linking lidamycin (LDM), an antitumor antibiotic with extremely potent cytotoxicity, to mAb Fab" fragment.	C 1027	51-60	FA complementation group B	Homo sapiens	135-138
12580049-4	2001	RESULTS: Hybridization of the entire cDNA populations to Atlas Arrays showed that lidamycin down-regulated the expression level of MMP-9 and up-regulated the expression level of TIMP-1.	C 1027	82-91	TIMP metallopeptidase inhibitor 1	Homo sapiens	178-184
12580049-4	2001	RESULTS: Hybridization of the entire cDNA populations to Atlas Arrays showed that lidamycin down-regulated the expression level of MMP-9 and up-regulated the expression level of TIMP-1.	C 1027	82-91	matrix metallopeptidase 9	Homo sapiens	131-136
30105903-3	2018	Lidamycin (LDM), an antitumor antibiotic with extremely potent cytotoxicity to cultured cancer cells, consists of an apoprotein (LDP) and an active enediyne chromophore (AE).	C 1027	0-9	carboxypeptidase Q	Homo sapiens	129-132
35582405-4	2022	In this study, a novel FR-directed, macropinocytosis-enhanced, and highly cytotoxic bioconjugate folate (F)-human serum albumin (HSA)-apoprotein of lidamycin (LDP)-active enediyne (AE) derived from lidamycin was designed and prepared.	C 1027	198-207	albumin	Mus musculus	114-157
32020213-4	2020	In animal experiments, ABD-LDP-Ec demonstrated notable selective distribution in pancreatic carcinoma xenografts by passive targeting of albumin captured in the blood and was retained in the tumor for 48 h. ABD-LDP-Ec and ABD-LDP-Ec-AE exhibited inhibitory activity in cell proliferation and AsPC-1 xenograft growth, and ABD-LDP-Ec-AE increased the tumor growth inhibition rate by 20% compared with natural LDM.	C 1027	407-410	carboxypeptidase Q	Homo sapiens	27-30
31555598-3	2019	Previously, we showed that an engineered cytotoxic fusion protein anti-CD19(Fab)-LDM (lidamycin), can induce apoptosis of B-lymphoma cells.	C 1027	86-95	CD19 molecule	Homo sapiens	71-75
31555598-3	2019	Previously, we showed that an engineered cytotoxic fusion protein anti-CD19(Fab)-LDM (lidamycin), can induce apoptosis of B-lymphoma cells.	C 1027	86-95	FA complementation group B	Homo sapiens	76-79
31555598-3	2019	Previously, we showed that an engineered cytotoxic fusion protein anti-CD19(Fab)-LDM (lidamycin), can induce apoptosis of B-lymphoma cells.	C 1027	86-95	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	81-84
30542729-8	2019	In addition, western blot analysis revealed that treatment of the K562 cells with lidamycin at low concentrations upregulated the expression of caspase-8 and caspase-3.	C 1027	82-91	caspase 8	Homo sapiens	144-153
30542729-8	2019	In addition, western blot analysis revealed that treatment of the K562 cells with lidamycin at low concentrations upregulated the expression of caspase-8 and caspase-3.	C 1027	82-91	caspase 3	Homo sapiens	158-167
30542729-11	2019	Low concentrations of lidamycin triggered erythroid differentiation among K562 cells, indicated by morphological changes, increased hemoglobin content, and the expression of cell surface antigens such as CD71.	C 1027	22-31	transferrin receptor	Homo sapiens	204-208
30542729-12	2019	Additionally the expression of GATA-binding factor 1 (GATA-1) protein in low concentration lidamycin-treated K562 cells was increased.	C 1027	91-100	GATA binding protein 1	Homo sapiens	31-52
30542729-13	2019	The results of the present study suggest that a low-concentration lidamycin exerts effects on apoptosis and erythroid differentiation induction by increasing the expression of caspases and GATA-1 protein.	C 1027	66-75	caspase 8	Homo sapiens	176-184
8213168-10	1993	Fab-C1027 conjugate showed more marked antitumor effect in vivo than free C1027.	C 1027	4-9	FA complementation group B	Homo sapiens	0-3
30742941-2	2019	In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30+/ALK+ anaplastic large cell lymphoma (ALCL).	C 1027	94-103	TNF receptor superfamily member 8	Homo sapiens	64-68
30742941-2	2019	In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30+/ALK+ anaplastic large cell lymphoma (ALCL).	C 1027	94-103	TNF receptor superfamily member 8	Homo sapiens	89-93
30742941-2	2019	In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30+/ALK+ anaplastic large cell lymphoma (ALCL).	C 1027	94-103	TNF receptor superfamily member 8	Homo sapiens	89-93
30105903-5	2018	Results show that the IC50 values of albumin-lidamycin conjugate (HSA-LDP-AE) for a variety of tested cancer cells were at subnanomolar levels.	C 1027	45-54	carboxypeptidase Q	Homo sapiens	70-73
29757658-3	2018	Fv is the fragment of an anti-EGFR antibody, D3 is the domain III of human serum albumin (HSA), LDP is the apoprotein of the antitumor antibiotic lidamycin (LDM), and AE is an extremely cytotoxic enediyne chromophore derived from LDM.	C 1027	146-155	carboxypeptidase Q	Homo sapiens	96-99
29344233-0	2017	Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway.	C 1027	0-9	prominin 1	Homo sapiens	20-25
29344233-0	2017	Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway.	C 1027	0-9	notch receptor 1	Homo sapiens	73-78
29344233-2	2017	In the present study, the effect of lidamycin (LDM) on CD133 expression in hepatocellular carcinoma (Huh7 cells) was evaluated and the potential molecular mechanism was investigated.	C 1027	36-45	prominin 1	Homo sapiens	55-60
28498434-4	2017	Based on the findings, the antitumor activity of an EGFR/IGF-1R bispecific and enediyne-energized fusion protein EGF-LDP-IGF-AE, which we constructed recently by fusing two ligands (EGF and IGF-1) with an enediyne antibiotic lidamycin (LDM), on ESCC were evaluated.	C 1027	225-234	epidermal growth factor receptor	Homo sapiens	52-56
28498434-4	2017	Based on the findings, the antitumor activity of an EGFR/IGF-1R bispecific and enediyne-energized fusion protein EGF-LDP-IGF-AE, which we constructed recently by fusing two ligands (EGF and IGF-1) with an enediyne antibiotic lidamycin (LDM), on ESCC were evaluated.	C 1027	225-234	insulin like growth factor 1 receptor	Homo sapiens	57-63
28498434-4	2017	Based on the findings, the antitumor activity of an EGFR/IGF-1R bispecific and enediyne-energized fusion protein EGF-LDP-IGF-AE, which we constructed recently by fusing two ligands (EGF and IGF-1) with an enediyne antibiotic lidamycin (LDM), on ESCC were evaluated.	C 1027	225-234	insulin like growth factor 1	Homo sapiens	57-62
27991698-2	2017	Herein, the therapeutic effects of NGR-LDP-AE, a fusion protein composed of CD13-targeting peptide NGR and antitumor antibiotic lidamycin, on human liver cancer and its mechanism were studied.	C 1027	128-137	reticulon 4 receptor	Homo sapiens	35-38